Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Conditions
Brief summary
Phase Ib/II clinical study of AK129 combined with chemotherapy with or without cadonilimab in first-line treatment of advanced HER2 negative gastric cancer or gastroesophageal junction adenocarcinoma
Interventions
DRUGDrug: AK129 Drug：oxaliplatin Drug：capecitabine
AK129 is administered intravenously according to the frequency every three weeks(Q3W) and different dosage of administration at different stages.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
DRUGDrug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine
AK129 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages. Cadonilimab is administered intravenously according to the frequency and dosage 10mg/kg Q3W.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
Sponsors
Akeso
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase 1b/II, open-label, 2-part, multicenter, non-randomized, multiple-dose study
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The subject must sign the written informed consent form(ICF) voluntarily. 2. Aged ≥ 18 to ≤ 75 years,male and female at the time of signing the ICF. 3. Histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction (GEJ). 4. Inoperable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. 5. Participants had not previously received systemic therapy for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. 6. According to RECIST v1.1 criteria, subjects had at least one measurable tumor target.
Exclusion criteria
1. Subjects with known HER2 positive gastric or gastroesophageal junction adenocarcinoma. 2. Histopathological examination confirmed other pathological types. 3. Had received palliative local therapy for non-target lesions within 2 weeks before the first administration. 4. Past treatment with immune checkpoint inhibitors,immune checkpoint agonists,immune cell therapy and any treatment targeting the immune mechanism of tumor action. 5. History of gastrointestinal perforation and fistula within 6 months before the first dose. 6. Active or previously documented inflammatory bowel disease,inability to swallow, malabsorption syndrome. 7. Active malignancy within the last 3 years. 8. Active or untreated brain metastases, meningeal metastases, spinal cord compression, or pia meningeal disease are known to exist. 9. The presence of clinical symptoms of pleural effusion, pericardial effusion, or abdominal effusion, or the need for frequent drainage. 10. There was an active autoimmune disease that required systemic treatment within 2 years prior to the start of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of adverse events(AE) | Up to approximately 2 years | Incidence and severity of AEs is aim to evaluate the safety of AK129 combined with chemotherapy with or without cadonilimab |
| Incidence of serious adverse events(SAE) and suspected unexpected serious adverse reactions(SUSAR) | Up to approximately 2 years | Incidence of SAE and SUSAR is aim to evaluate the safety of AK129 combined with chemotherapy with or without cadonilimab |
| Incidence of dose-limiting toxicity(DLT) | Up to approximately 2 years | The purpose of DLT is to find the Phase II recommended dose(RP2D) or Maximum Tolerated Dose(MTD) |
| Clinically significant changes in safety/laboratory evaluation parameters and AEs that led to treatment termination or suspension | Up to approximately 2 years | Clinically significant changes in safety/laboratory evaluation parameters and AEs that led to treatment termination or suspension is aim to evaluate the safety of AK129 combined with chemotherapy with or without cadonilimab |
| Objective Solution Rate (ORR) based on RECIST v1.1 | Up to approximately 2 years | The purpose of ORR is aim to evaluate the antitumor effect,and ORR is proportion of subjects with complete response(CR) or partial response(PR), based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum AK129, cadonilimab concentration, blood concentration-time curve and derived PK argument | Up to approximately 2 years | Serum AK129, cadonilimab concentration, blood concentration-time curve and derived PK argument to evaluate the Pharmacokinetics(PK). |
| Disease control rate(DCR) | Up to approximately 2 years | Disease control rate(DCR) is defined as the proportion of subjects achieving a best of response(BOR) of confirmed CR or PR or stable disease(SD) per RECIST v1.1. |
| Number and percentage of subjects with anti-drug antibodies (ADA) for AK129 and cadonilimab | Up to approximately 2 years | Number and percentage of subjects with anti-drug antibodies (ADA) for AK129 and cadonilimab will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs). |
| duration of response(DoR) | Up to approximately 2 years | Duration of response(DoR) is defined as the period from the first documentation of confirmed response(CR or PR) to the first documentation of progressive disease(PD) as per RECIST v1.1 or death due to any cause, whichever occurs first. |
| time to response(TTR) | Up to approximately 2 years | Time to response(TTR) is defined as the time from the first dose of investigational products until the first confirmation of CR or PR. |
| progression-free survival(PFS) | Up to approximately 2 years | Progression-free survival(PFS) is defined as the time from the first dose of investigational products until documentation of progressive disease(PD) as per RECIST v1.1 or death due to any cause, whichever occurs first. |
| overall survival(OS) | Up to approximately 2 years | Overall survival(OS) is defined as the time from the first dose of investigational products until death due to any cause. |
Countries
China
Contacts
Primary ContactXiao Xu, MD, PhD
Outcome results
None listed